Estimates of prostate cancer burden in Italy

Cancer Epidemiology

Volumn 40, Issue , 2016, Pages 166-172

  Capocaccia, R ^a   Foschi, R ^a   Zucchetto, A ^b   Valdagni, R ^a   Nicolai, N ^a   Maffezzini, M ^a   Gatta, G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Incidence; Mortality; Prevalence; Prostate cancer; Time trends

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; GROUPS BY AGE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; ADOLESCENT; CHILD; ETHNIC GROUP; FACTUAL DATABASE; INCIDENCE; INFANT; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; PROGNOSIS; PROSTATIC NEOPLASMS; REGISTER; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; ETHNIC GROUPS; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; ITALY; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROSTATIC NEOPLASMS; REGISTRIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84960096680     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2015.12.004     Document Type: Article

References (26)

1. GLOBOCAN 2012. Available from: URL: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
2. Center M.M., Jemal A., Lortet-Tieulent J., Ward E., Ferlay J., Brawley O., et al. International variation in prostate cancer incidence and mortality rates. Eur. Urol. 2012, 61:1079-1092.
3. AIRTUM I., numeri del Cancro in Italia, 2013, AIOM e CCM 2013. Available from: URL: http://www.salute.gov.it/imgs/C_17_pubblicazioni_2250_allegato.pdf.
4. Dal Maso L., Guzzinati S., Buzzoni C., Capocaccia R., Serraino D., Caldarella A., et al. Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types. Ann. Oncol. 2014, 25:2251-2260.
5. Rossi S., Capocaccia R., De Angelis R., Gatta G. Cancer burden in Italian regions. Tumori 2013, 99.
6. Verdecchia A., Capocaccia R., Egidi V., Golini A. A method for the estimation of chronic disease morbidity and trends from mortality data. Stat. Med. 1989, 8:201-216.
7. ISTAT, Statistiche sulle cause di morte anno, 2008; 2015. Available from: URL: (accessed 30.04.15). http://www.istat.it/dati/dataset/20110412_00/.
8. Geo Demo Demografia in cifre ISTAT, 2015. Available from: URL: http://demo.istat.it/.
9. De Angelis G., De Angelis R., Frova L., Verdecchia A. MIAMOD: computer package to estimate chronic disease morbidity using mortality and survival data. Comput. Methods Progr. Biomed. 1994, 44:99-107.
10. World Health Organisation International Classification of Diseases, 1975 1997, WHO, Geneva. 9th ed.
11. Capocaccia R., Gavin A., Hakulinen T., Lutz J.M., Sant M. Survival of cancer patients in Europe, 1995-2002: the EUROCARE-4 study. Eur. J. Cancer 2009, 45:901-1094.
12. ITACAN 2015. Available from: URL: http://itacan.ispo.toscana.it/italian/itacan.htm.
13. Draisma G., Etzioni R., Tsodikov A., Mariotto A., Wever E., Gulati R., et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J. Natl. Cancer Inst. 2009, 101:374-383.
14. D'Ambrosio G.G., Campo S., Cancian M., Pecchioli S., Mazzaglia G. Opportunistic prostate-specific antigen screening in Italy: 6 years monitoring from the Italian general practice database. Eur. J. Cancer Prev. 2010, 19:413-416.
15. World Cancer Research Fund International, Continuous Update Project Report: Diet, Nutrition, Physical Activity, and Prostate Cancer. 2014. Available at: http://www.wcrf.org/sites/default/files/Prostate-Cancer-2014-Report.pdf.
16. Kvale R., Auvinen A., Adami H.O., Klint A., Hernes E., Moller B., et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J. Natl. Cancer Inst. 2007, 99:1881-1887.
17. Edwards B.K., Noone A.M., Mariotto A.B., Simard E.P., Boscoe F.P., Henley S.J., et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014, 120:1290-1314.
18. Australian Institute of Health and Welfare Cancer in Australia: actual incidence data from 1991 to 2009 and mortality data from 1991 to 2010 with projections to 2012. Asia Pac. J. Clin. Oncol. 2013, 9:199-213.
19. Howard D.H., Tangka F.K., Guy G.P., Ekwueme D.U., Lipscomb J. Prostate cancer screening in men ages 75 and older fell by 8 percentage points after Task Force recommendation. Health Aff. (Millwood) 2013, 32:596-602.
20. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 185-191.
21. Legacy Screening Portal. Available from: URL: http://www.screening.nhs.uk/prostatecancer.
22. Canadian Task Force on Preventive Health Care Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ 2014, 10.1505/cmaj.140703.
23. Trama A., Foschi R., Larranaga N., et al. Survival of male genital cancers (prostate, testis and penis) in Europe: results from the Eurocare-5 study. Eur. J. Cancer 2015, 51:2206-2216.
24. Quon H., Loblaw A., Nam R. Dramatic increase in prostate cancer cases by 2021. BJU Int. 2011, 108:1734-1738.
25. Clèries R., Ribes J., Buxo M., Ameijide A., Marcos-Gragera R., Galceran J., et al. Bayesian approach to predicting cancer incidence for an area without cancer registration by using cancer incidence data from nearby areas. Stat. Med. 2012, 31(10):978-987.
26. Boccardo F., Ciatto S., Martorana G. Associazione Italiana di Epidemiologia, Associazione Italiana di Medicina Nucleare, Associazione Italiana di Oncologia Medica, et al. Italian national consensus conference on prostate cancer screening-final consensus document. Florence: Int. J. Biol. Markers 2003, 18(May (17)):238-240.